Nicotine Patch Bioequivalence Study

• Status: Completed
• Trial end date: 2012-09-01

Summary

The purpose of this study is to compare the relative bioavailability of nicotine following single application of a new transdermal formulation to that of a reference formulation.

4 single 24hour applications separated by 48hour intervals.

• Phase: Phase 1

Details

• Lead Sponsor: Pierre Fabre Medicament
• Treatments: Nicotine